secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001104659-24-110552
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts
--------------------------------------------------------------------------------

- Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.
- Gross margin ~68% vs 69% in prior-year quarter.
- Cash and equivalents $17.3M at Sept 30, 2024, down from $46.7M at Dec 31, 2023.
- Cost-cutting measures expected to reduce FY2025 operating expenses by $5M-$10M annualized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/0001104659-24-110552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/tm2426600d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-110552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer